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ABSTRACT 
Rationale Dietary nitrate supplementation improves skeletal muscle oxygen utilisation and 
vascular endothelial function. We hypothesised that these effects might be sufficient to improve 
exercise performance in patients with COPD and hypoxia severe enough to require 
supplemental oxygen. 
Methods We conducted a single-centre, double-blind, placebo-controlled, cross-over study, 
enrolling adults with COPD who were established users of long-term oxygen therapy. 
Participants performed an endurance shuttle walk test, using their prescribed oxygen, three 
hours after consuming either 140 mL of nitrate-rich beetroot juice (BRJ) (12.9 mmol nitrate), 
or placebo (nitrate-depleted BRJ). Treatment order was allocated (1:1) by computer generated 
block randomisation. 
Measurements The primary outcome was endurance shuttle walk test time. Secondary 
outcomes included area under the curve to isotime for fingertip oxygen saturation and heart 
rate parameters during the test, blood pressure and endothelial function assessed using flow 
mediated dilatation. Plasma nitrate and nitrite levels as well as fraction of exhaled nitric oxide 
were also measured. 
Main Results 20 participants were recruited, and all completed the study. Nitrate-rich BRJ 
supplementation prolonged exercise endurance time in all participants as compared to placebo; 
median (IQR) 194.6 (147.5, 411.7) seconds vs 159.1 (121.9, 298.5) seconds; estimated 
treatment effect 62 (33 to 106) seconds (p<0.0001); and improved endothelial function; NR-
BRJ group +4.1 (-1.1, 14.8)% vs PL-BRJ group -5.0 (-10.6, -0.6)%; p = 0.0003. 
Conclusion Acute dietary nitrate supplementation increases exercise endurance in COPD 
patients who require supplemental oxygen.  
Word Count: 231/250 
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Key Messages 
What is the key question? 
• Can dietary nitrate supplementation enhance exercise performance in individuals with
a hypoxic COPD phenotype?
What is the bottom line? 
• In a double-blind, placebo-controlled, randomised crossover study, an acute dose of
dietary nitrate increased endurance shuttle walk time in individuals with a hypoxic
COPD phenotype.
Why read on? 
• As COPD becomes more severe, hypoxaemia may develop which impacts on the ability
to perform day to day activities. Interventions which improve endothelial function as
demonstrated here, and increase the efficiency of oxygen use may help to address this.
Keywords 
Dietary nitrate supplementation, nitric oxide, chronic obstructive pulmonary disease, exercise, 




People with chronic obstructive pulmonary disease (COPD) may develop hypoxaemia as the 
condition becomes more severe, impacting on their ability to perform day to day activities. 
Mechanisms include ventilation perfusion mismatch, reduced cardiac output due to 
hyperinflation and pulmonary vascular limitation as well as reduced muscle efficiency 1-5. In 
individuals who are sufficiently hypoxaemic long-term oxygen therapy (LTOT) improves 
survival and in many individuals ambulatory oxygen (AOT) improves exercise performance 6.  
 
Nitric oxide (NO) has potential as a modulator of exercise performance. A ubiquitous 
signalling molecule, NO is involved in a number of processes at a tissue and cellular level 
including; mitochondrial and cellular respiration 7,8, glucose uptake into skeletal muscle 9, 
skeletal muscle contraction 10 11, neurotransmission 12 and fatigue development 13. NO is 
produced both by oxygen-dependant nitric oxide synthases catalysing its production from L-
arginine and an alternative Nitrate(NO3
-)-Nitrite(NO2
-)-NO pathway 14. The latter can be 
influenced by supplementation with exogenous dietary NO3
- and is enhanced in conditions of 
hypoxia and low pH as found in exercising skeletal muscle 15.  
 
Dietary NO3
- supplementation has been shown to reduce the oxygen cost of exercise in healthy 
individuals in normoxic conditions 16,17 and in conditions of hypoxaemia 18-23. Recently our 
research group has shown that it augments the improvements in exercise capacity seen in 
people with COPD following pulmonary rehabilitation 24,25. We have also previously shown 
that dietary nitrate supplementation reduces the oxygen cost of exercise during endurance cycle 
ergometry in COPD 26. However, that study, which excluded patients who required 
supplemental oxygen, did not demonstrate an improvement in exercise capacity. 
 
The aim of the present study was therefore to assess the acute effect of dietary supplementation 
in the form of nitrate-rich beetroot juice (NR-BRJ) on exercise performance in individuals with 
COPD who require supplemental oxygen on exertion, hypothesising that this would increase 
exercise capacity, measured as endurance shuttle walk time (ESWT), as well as improving 




MATERIALS AND METHODS 
Study design 
The effect of dietary nitrate supplementation on exercise performance in hypoxia (EDEN-OX) 
study was a single-centre, double-blind, placebo controlled, randomised cross-over trial 
comparing the effects of dietary nitrate supplementation to a matched placebo in individuals 
with COPD who require long-term oxygen therapy (LTOT) and use ambulatory oxygen 
therapy (AOT) during exercise. All participants provided informed consent and the study was 
approved by the London Chelsea Research and Ethics Committee (Ref: 15/LO/0975) and 
conducted in line with the principles of the Declaration of Helsinki. The study was registered 
prospectively on a publicly accessible database (ISRCTN14888729). The data presented here 
relate only to the planned COPD cohort in that study. 
 
People with GOLD grade II-IV COPD 27 who were established users of LTOT, in accordance 
with NICE guidelines 28 were recruited from outpatient clinical services at Royal Brompton 
and Harefield NHS Foundation Trust (NW London), between 4th November 2016 and the 8th 
August 2017, with the last participant’s final visit completed on the 15th of January 2018. 
 
Exclusion criteria for the study included clinical instability (i.e. less than one month after an 
exacerbation), significant comorbidity limiting exercise tolerance, significant renal impairment 
(estimated glomerular filtration rate <50mL.min-1), hypotension (systolic blood pressure 
<100mmHg), pregnancy, use of NO3
--based medicine or phosphodiesterase V inhibitors or the 
presence of other conditions that might be influenced by nitrate supplementation (i.e., 
ischaemic heart disease or peripheral vascular disease). These conditions were assessed at the 




The intervention was a commercially available concentrated NO3
--rich BRJ (NR-BRJ) (98%) 
drink cut with organic lemon juice (2%), containing 0.8 g, 12.9 mmol of NO3
- (140mL Beet-
It® SPORT shot, James White Drinks, Ipswich, UK). The placebo beetroot juice (PL-BRJ) 
produced by James White Ltd was 140mL of the same beverage in which nitrate was removed 
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by a standardised method of passing the juice, prior to pasteurisation, through an ion exchange 
column, containing Purolite A520E which exchanges NO3
- against chloride 29. The placebo-
BRJ (PL-BRJ) is identical in appearance, packaging, taste and smell, and also causes beeturia 
(orange to red discolouration of urine). 
 
Study conduct 
At an initial baseline visit the COPD assessment test (CAT), hospital anxiety and depression 
(HAD) and MRC dyspnoea scores were recorded as well as measurement of body composition 
by bioelectrical impedance analysis using a Bodystat 4000 device (Bodystat, Isle of Man, UK). 
Participants then performed two incremental shuttle walk tests (ISWT) to determine the 
walking speed to be used for the ESWT 30 and then a practice ESWT. All walking tests 
throughout the study were performed on the participant’s usual AOT flow rate and the method 
for carrying the AOT was recorded to ensure the same method was always used 
(Supplementary Appendix Study conduct. Figure E1. Study flow diagram). 
 
Prior to the two subsequent intervention visits and throughout the study period, participants 
were asked to avoid the use of antimicrobial mouthwash and chewing gum, as this has been 
shown to reduce the oral facultative bacteria whose nitrate reductase activity is essential for the 
metabolism of an oral nitrate load 31. They were asked to consume the same meal on the 
morning of each study assessment. This was to create as standardised conditions as possible, 
reducing differing levels of dietary NO3
- consumption as a source of variation within 
individuals, whilst not altering their usual diet greatly.  They were also asked to match caffeine 
consumption to standardise any ergogenic effect arising from it 32 and to avoid strenuous 
exercise in the 24h period prior to the intervention visits. 
 
The two intervention visits began at the same time of day (+/- 2h), with a minimum of a seven-
day washout period and a maximum one-month gap between them. Participants were randomly 
assigned to the order in which they received NR-BRJ or PL-BRJ using a computer-generated 
block randomisation list, block size 10, produced by an independent statistician. The 
researchers responsible for enrolment and outcome measurements remained blinded 
throughout the study and during data analysis. Following their arrival, after a 10-minute rest 
period, participants were observed consuming either the NR-BRJ or the PL-BRJ, empty bottles 
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were collected and recorded.  All outcome measures were undertaken three hours after 




The primary outcome was the ESWT time compared between treatment conditions. Given the 
cross-over design and taking 65 seconds (95%CI 45-85) to be the minimal clinically significant 
difference in the ESWT 30 and a pooled mean difference within individuals of 26 seconds for 
repeat testing, to have an 80% statistical power, with a significance level of 0.05, 16 
participants would be required to reject the null hypothesis that the active intervention was not 
superior to placebo. To allow for a 25% withdrawal rate a sample size of 20 was chosen. 
 
Plasma nitrate/nitrite levels and markers of oxidative stress 
Plasma NO3
- and NO2
- levels were used as a combined biomarker of NO3
- ingestion, 
metabolism and nitric oxide availability 33,34. Plasma samples were obtained on arrival and 
three hours after consumption of NR-BRJ or PL-BRJ (see Supplementary Appendix for full 
details). 
 
Oxidative stress biomarkers were assessed in plasma samples by a combination of three distinct 
readouts including antioxidant potential, i.e. measurement of the ferric-reducing ability of 
plasma (FRAP) 35, lipid oxidation products by thiobarbituric acid-reactive substances (TBARS)  
36 and total free thiols with normalisation for protein 37 (see Supplementary Appendix for full 
details). 
 
Fractional exhaled nitric oxide (FENO) 
FENO was measured as a steady exhalation rate of 50 mL.sec
-1 with a NIOX Mino (Aerocrine 
Systems, Solna, Sweden) at the screening visit and then at the intervention visits at baseline 
prior to NR-BRJ/PL-BRJ consumption and then at six further intervals (30, 60, 90, 120, 150 
and 180 minutes). Both the study participant and researchers were blinded to the results and an 
independent researcher, not directly involved with the trial, uploaded the data into a password 
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protected database. These data were only available to the researchers following the unblinding 
of the study. 
 
Endothelial function 
Endothelial function was assessed by flow medicated dilatation (FMD) of the brachial artery 
three hours after NR-BRJ/PL-BRJ consumption 38 using a high-resolution Doppler ultrasound 
to measure at baseline and sequentially over a period of 120 seconds after release of circulatory 
arrest of the upper arm 39. All measurements were performed by a single trained operator (see 
Supplementary Appendix for full details).  
 
Continuous oxygen saturations and heart rate analysis 
For each ESWT performed, pulse oximetry was recorded (Pulsox 300i Pulse Oximeter, Konica 
Minolta, Tokyo, Japan) throughout until the participant had recovered (recovery was defined 
by return of Borg dyspnoea scale to that recorded prior to the ESWT). To maintain blinding, 
the pulse oximeter display was covered throughout the testing and the data downloaded by an 
independent researcher, not directly involved with the trial, who uploaded the data to a 
password protected database. These data were only available to the researchers following 
unblinding of the trial.  
 
Statistical analysis 
Data are presented as mean (SD) or if not normally distributed as median and interquartile 
range (IQR). Differences in response between treatment conditions were assessed using a 
paired T-test or a Wilcoxon signed-rank test as appropriate. Treatment effect was estimated 
using the Hodges-Lehman estimate of shift parameters. The process of determining the 
Hodges-Lehman estimator entails estimating the average difference in outcomes (x-y) for 
every possible n(n+1)/2 pair and then deriving the overall median of all averages (the Hodges-
Lehmann estimator). A distribution-free confidence interval is estimated using large-sample 
approximation. Analysis was performed using SPSS version 24 for Windows (SPSS Software, 
Chicago, Illinois, USA) and Stata version 16.1 for Windows (StataCorp 2019, Stata Statistical 




To perform the comparison of continuous oxygen saturations (SpO2) and heart rate (HR) 
between the two treatment conditions, individual ESWT data periods were subjected to a 30 
second rolling average using MATLAB (MATLAB and Statistics Toolbox Release 2017a, The 
MathWorks, Inc., Natick, Massachusetts, USA) and then expressed as percentages of isotime 
(defined as the duration of the shortest of the two ESWT). These individual responses were 
then grouped to allow analysis of heart rate and SpO2 against percentage of isotime (plotted at 
the midpoint of each 10th percentile of isotime). The area under the curve (AUC) was assessed 
for each individual participant and the two treatment conditions compared using a Wilcoxon 
signed-rank test. Figures were prepared using GraphPad Prism version 6.0 for Windows 




We screened 67 people for eligibility (Figure 1); 31 declined to participate, seven had a 
comorbidity precluding participation and nine were not using supplementary O2. Of twenty 
participants enrolled in the study, ten were randomised to receive PL-BRJ first and ten NR-
BRJ first. All participants completed the study. Table 1 shows their baseline characteristics 
which were well-matched between the two order allocation groups. There were no serious 
adverse effects reported, though all participants reported beeturia. The average time between 






















Sex (% Female:Male) 30:70 50:50 1.0 40:60 
Age (Years) 68 (62, 73) 67 (64, 76) 0.7 67.6 (8.5) 
Caucasian (%) 100 100 1 100 
Smoking (Pack Years) 28 (14, 50) 64 (57, 96) 0.006 52 (21.6) 
BMI (kg.m-2) 24.3 (20.9, 29.0) 26.2 (21.4, 30.1) 0.5 25.2 (4.7) 
FFMI (kg.m-2) 18.4 (15.8, 20.1) 18.0 (14.0, 20.2) 0.8 18.1 (15.8, 19.9) 
Inhaled Medications     
 SABA (%) 91 100 0.4 95 
 LABA-ICS (%) 91 78 0.4 95 
 LAMA (%) 91 100 0.4 85 
Baseline Resting O2 Saturations 
FiO2 0.21 (%) 
92 (89, 94) 92 (89, 93) 0.8 92 
Pre-LTOT Prescription Baseline 
PaO2 (kPa) 
6.9 (6.0, 7.3) 6.6 (6.4, 7.2) 0.6 6.8 
Oxygen Prescription (L.min-1) 4 (2, 6) 2 (2, 4) 0.2 3.0 (2.0, 6.0) 
CAT Score 20 (18, 29) 19 (15, 28) 0.6 21 (8.0) 
MRC Dyspnoea Score 4 (4, 4) 4 (4, 4) 1.0 4 (4, 4) 
HAD Score A 4 (3, 7) 7 (2, 10) 0.3 4.0 (2.3, 8.8) 
HAD Score D 4 (4, 5) 5 (4, 7) 0.7 4.5 (4.0, 5.6) 
Systolic BP (mmHg) 139 (123, 149) 135 (115, 139) 0.1 137 (121, 143) 
Diastolic BP (mmHg) 76 (66, 83) 70 (65, 80) 0.4 73 (65, 82) 
MAP (mmHg) 94 (91, 104) 91 (85, 94) 0.2 92 (80, 100) 
Lung Function     
 FEV1 (L) 0.7 (0.6, 1.0) 0.7 (0.3, 1.0) 0.3 0.7 (0.6, 1.0) 
 FVC (L) 2.7 (1.9, 3.1) 1.6 (1.4, 3.2) 0.3 2.7 (1.6, 3.1) 
 FEV1/FVC Ratio 0.3 (0.3, 0.3) 0.3 (0.2, 0.4) 1.0 0.3 (03, 0.3) 
 RV %Predicted 211 (181, 235) 212 (188, 233) 0.8 212 (186, 233) 
 TLco %Predicted 33 (19, 45) 36 (28, 44) 0.9 32 (19. 44) 
GOLD Stage     
 III (%) 22 45 1.0 35 
 IV (%) 78 55 1.0 65 
ISWT Distance (meters) 300 (280, 360) 370 (220, 280) 0.04 279 (70) 




Data in order of intervention, either NR-BRJ or PL-BRJ first. Data shown are median (IQR), 
mean (SD) or percentage (%). P value is for independent t-test, or Mann-Whitney test 
comparing groups.  
 
Abbreviations: NR – Nitrate-rich; PL – Placebo; BRJ – Beetroot Juice; BMI – Body Mass 
Index; FFM – Fat Free Mass; FFMI – Fat Free Mass Index: SABA – Short Acting Beta Agonist; 
LABA – Long Acting Beta Agonist; ICS – Inhaled Corticosteroid; LAMA – Long Acting 
Muscarinic Agonist; FiO2 – Fraction of Inspired Oxygen, LTOT – Long Term Oxygen Therapy; 
CAT – COPD Assessment Test; MRC – Medical Research Council; HADS A – Hospital Anxiety 
Depression Scale Anxiety; HADS D – Hospital Anxiety Depression Scale Depression; BP – 
Blood Pressure; MAP – Mean Arterial Pressure; FEV1 – Forced Expiratory Volume in 1 
Second; FVC – Forced Vital Capacity; RV – Residual Volume; TLcoc – Transfer Factor for 
Carbon Monoxide Corrected for haemoglobin; PaO2 – Partial Pressure of Oxygen; GOLD – 
Global Initiative for Chronic Obstructive Lung Disease; ISWT – Incremental Shuttle Walk Test; 
ESWT – Endurance Shuttle Walk Test 
 
Exercise outcomes 
Exercise endurance time was longer for all study participants after NR-BRJ compared to PL-
BRJ (Figure 2); median (IQR) ESWT time; NR-BRJ 194.6 (147.5, 411.7) seconds vs PL-BRJ 
159.1 (121.9, 298.5) seconds, estimated treatment effect 62.5 (95% CI 33 to 106) seconds; p 
0.000089. There was no evidence of an intervention order effect (Supplementary Appendix 
Figure E2). There was one individual who was a clear outlier for exercise endurance response. 
However, a sensitivity analysis, removing their data led to a slight change in primary study 
outcome but not the overall statistical significance with median (IQR) ESWT time; NR-BRJ 
193.8 (145, 389.6) seconds vs PL-BRJ 158.2 (121.6, 236.6) seconds, estimated treatment effect 
56.5 (95% CI 30 to 88) seconds indicating a significant increase in the ESWT time with NR-
BRJ, p=0.0001 (Supplementary Appendix Results E1). 
 
Pulse oximetry data were available for only 18 participants, because recording failed for two 
of them. The average area under the curve for oxygen saturations was higher in the NR-BRJ 
group compared to PL-BRJ. These differences were more apparent at isotime and peak exercise, 
with no difference at rest, during warm up or recovery (Figure 3 Panel A and Supplementary 
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Table E1). The estimated treatment effect was also statistically significant 43.69 (29.09 to 
58.28), p < 0.0001- The area under the curve for HR response to NR-BRJ or PL-BRJ did not 
show any difference. The estimated treatment effect was also not statistically significant (-
41.17 (-116.74 to 34.40), p = 0.27). (Figure 3 Panel B and Supplementary Appendix Table E1). 
 
Endothelial function and blood pressure 
Two participants declined to have the FMD assessment, therefore data were available for 18 
participants. At 180 minutes following dosing FMD increased with NR-BRJ 4.1 (-1.1 to 14.8) 
% compared to placebo -5.0 (-10.6 to -0.6) %, estimated treatment effect -11.9 (95%CI -18.9 
to -7.15) %; p = 0.0003 (Figure 4).  
 
There was no statistically significant difference in the change in blood pressure parameters 
from pre-dosing levels between NR-BRJ and PL-BRJ (Figure 5); median (IQR) ∆sBP: NR-
BRJ -1.5 (15.0, 10.8) mmHg vs PL-BRJ -0.5 (-10.5, 6.8) mmHg, estimated treatment effect 1 
(95%CI -5.5 to 7.0) mmHg; p = 1.0; ∆dBP: NR-BRJ -4.0 (-14.0, 7.0) mmHg vs PL-BRJ -1.0 
(-9.3, 5.0) mmHg, estimated treatment effect 1 (95%CI -3 to 5) mmHg, p = 0.481; MAP: NR-
BRJ -5.0 (-15.3, 6.0) mmHg vs PL-BRJ -2.5 (-13.5, 7) mmHg, estimated treatment effect 1.5 
(95%CI -3.5 to 5) mmHg; p = 0.359. 
 
Plasma nitrate and nitrite levels and oxidative stress markers 
Paired data on plasma NO2
- and NO3
- concentrations were available for 19 participants, as one 
individual declined sampling. Following supplementation with NR-BRJ there was an 84% 
increase in plasma NO2
- and an 887% increase in plasma NO3
- at 180 minutes post 
supplementation, but no change with placebo (Figure 6 and Supplementary Appendix Table 
E2). Both, the NR-BRJ and PL-BRJ supplements were analysed for NO2
- and NO3
- content as 
well (Supplementary Appendix Table E3). The change in plasma NO3
- and NO2
- from baseline 
to 180 seconds was calculated and used to estimate the treatment effect of NR-BRJ. The 
treatment effect of NO3
- was 550 (461 to 639) µM. The results suggest that this was higher for 
NR-BRJ than PL-BRJ and this change was statistically significant, p=0.0003. The treatment 
effect of NO2- was 0.248 (0.138 to 0.408) µM. The results suggest that this was higher for NR-




There was no statistically significant difference in measures of oxidative stress following acute 
consumption of either supplement; FRAP: NR-BRJ 1018 (853.0, 1125) µM vs PL-BRJ 930.2 
(836.8, 1073) µM; p = 1.0; TBARS: NR-BRJ 1.499 (0.855, 3.209) mM vs PL-BRJ 0.971 (0.766, 
1.614) mM; p = 0.4; total free thiol per protein: NR-BRJ 7.079 (5.961, 8.115) µmol.g-1 protein 
vs PL-BRJ 6.942 (5.768, 8.026) µmol.g-1 protein; p = 0.5) (Supplementary Appendix Figure 
E3). 
 
Paired measures of FENO were available for 16 participants at all seven time points (Figure 7, 
and Supplementary Appendix Table E5). For four participants, there was device failure 
resulting in no data being recorded. The median (IQR) AUC for when the subjects were on PL-
BRJ was 3622.5 (3181.9, 4796.9) and the corresponding results for when the subjects were on 
NR-BRJ was 9440.6 (6273.8, 11831.3) and the treatment effect with its 95% CI was 5407 
(3096 to 7576), p=0.0011. The results suggest that the FENO levels while the subjects were on 
NR-BRJ were significantly higher than when they were on PL-BRJ. Post-acute (zero minutes) 
supplementation with NR-BRJ FENO increased by 184% at 180 minutes post supplementation.  
 
DISCUSSION 
The major finding of this study was that, in people with COPD who are hypoxic to the extent 
that they meet criteria for long term oxygen therapy, dietary NO3
- supplementation improves 
exercise capacity compared to placebo. The improvement in ESWT time that we observed was 
accompanied by less desaturation during exercise. Supplementation also improved endothelial 
function assessed using FMD. In line with previous observations 24,25, blood pressure was 
numerically lower as well but the difference in response was not statistically significant. 
 
Significance of findings 
Although studies have previously considered dietary NO3
- supplementation in COPD with 
inconsistent results 24-26,40, this is the first stratified medicine approach focusing on the specific 
phenotype of individuals with COPD with hypoxaemia requiring LTOT. Our previous study, 
in non-hypoxaemic COPD patients, found that there was a reduction in the oxygen cost of 
exercise during cycle ergometry yet no improvement in exercise capacity 26. In conditions of 
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hypoxia, the L-arginine-NOS pathway is compromised while the NO3
--NO2
--NO pathway is 
facilitated due to a lesser inhibition of NO2
- bioactivation by oxygen 14,20,22. As such, dietary 
NO3
- supplementation could be expected to have more impact in hypoxic rather than normoxic 
individuals, both through effects in skeletal muscle and impacts on the pulmonary vasculature.  
 
The mechanism by which ESWT lengthened is likely to involve multiple synergistic pathways. 
The finding of relatively preserved oxygen saturation during exercise in the NO3
--
supplemented condition could reflect either more efficient oxygen utilisation peripherally or a 
beneficial impact on central haemodynamics associated with/related to reduced hypoxia 
induced pulmonary vasoconstriction, or a combination of the two. Despite each participant 
using their prescribed oxygen for each walk test, there was an observed desaturation in the 
placebo arm. This could mean that their oxygen prescription may have been insufficient and 
that a higher flow rates might also have increased exercise capacity. This finding of the 
attenuation of desaturation by NR-BRJ may well be explained by the enhancement of the NO3
-
-NO2
--NO pathway in conditions of hypoxia. The observation that NO3
- supplementation was 
associated with improvements in endothelial function assessed using FMD, is likely to be 
relevant to the acute mechanism of benefit from NO3
- supplementation, but also raises the 
possibility that longer-term dosing might reduce the risk of vascular events which are common 
in COPD. The effects seen are almost certainly not COPD-specific and work is needed to 
investigate possible benefits in other long-term lung conditions associated with hypoxia, 
including interstitial lung diseases and the various categories of pulmonary hypertension. 
 
The estimated treatment effect of dietary NO3
- supplementation on ESWT time found in this 
study was 62.5 seconds, which falls fractionally short of the MID defined in pharmacotherapy 
trials as 65 seconds 30. However, in pharmacological trials where the ESWT time is the outcome, 
interventions are typically administered over weeks or months. The demonstration of an effect 
of similar magnitude in a single dose study is therefore encouraging though further studies of 
longer-term use will be needed before any clinical recommendations can be made.  
 
Study limitations 
The use of a robust placebo strengthens the reliability of the findings, as does the fact that the 
improvement in walking time was accompanied by an appropriate physiological response 
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(lower heart rate and higher oxygen saturation). An additional strength was the use of a walking 
rather than cycling test, which is of clinical relevance to patients as it reflects most individuals’ 
main form of exercise and daily physical activity. This was a single dose study and therefore 
questions remain as to the impact that regular dosing might have and whether this would 
translate into meaningful clinical effects. The dose used was selected based on previous studies 
but future work should investigate whether there is a dose response or ceiling effect.  We have 
also shown that the NR-BRJ does indeed contain a higher quantity of NO3
- and provide 
independent confirmation that NO3
- is only present at very low levels in the placebo juice used 
in our study.  
 
Conclusion 
Beetroot juice is cheap and readily accessible and has the potential to be used widely as a 
dietary supplement if effective in specific patient groups. Its beneficial effects appear to be 
mediated by inorganic nitrate without affecting plasma redox status, upon acute administration. 
Further mechanistic work is needed to work out the relative impact of the possible mechanisms, 
in particular the impact of muscle vs pulmonary or cardiac/systemic circulation effects, and 
longer-term studies will be needed to establish if the effects on exercise performance and 
endothelial function observed here translate into clinically meaningful benefits. 
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Figure 1. CONSORT diagram for recruitment and trial completion 
Abbreviations: NR-BRJ – Nitrate-rich Beetroot Juice; PL-BRJ – Placebo Beetroot Juice 
 
Figure 2. Effect of dietary nitrate supplementation on endurance shuttle walk time 
ESWT time (seconds) for PL-BRJ and NR-BRJ dosing conditions. Data presented as individual 
ESWT times (seconds) in both dosing conditions. Wilcoxon signed-rank test was used to 
compare ESWT time between the different dosing conditions. NR-BRJ 194.6 (147.5, 411.7) 
seconds vs PL-BRJ 159.1 (121.9, 298.5) seconds, estimated treatment effect 62 seconds (95% 
CI 33 to 106); p = 0.000089.  
 
Abbreviations: ESWT – Endurance Shuttle Walk Test; PL-BRJ – Placebo Beetroot Juice; NR-
BRJ – Nitrate-rich Beetroot Juice 
 
Figure 3. Effect of dietary nitrate supplementation on isotime O2 saturation and heart 
rate during endurance shuttle walk test 
Panel A. O2 saturation analysis in the NR-BRJ (red) and PL-BRJ (black) dosing conditions at 
10th percentiles of isotime and at rest, warm-up, peak exercise and recovery. Data presented as 
median and IQR. The area under the curve for each treatment group was estimated and reported 
as mean (SD). The results for Saturations for when the subjects were on PL-BRJ were 1161.85 
(47.59) and the results for when the subjects on NR-BRJ were 1205.54 (46.39). The treatment 
effect was estimated to be 43.69 (29.09 to 58.28) p < 0.0001. The results suggest that on the 
average the area under the curve for saturations was higher when on NR-BRJ than when on 
PL-BRJ. These differences tended to show more during the isotime and peak periods 
 
Panel B. Heart rate (HR) analysis in the NR-BRJ (red) and PL-BRJ (black) dosing conditions 
at 10th percentiles of isotime and at rest, warm-up, peak exercise and recovery. Data presented 
as median and IQR. The area under the curve for each treatment group was estimated and 
reported as mean (SD). The mean (SD) area under the curve for the HR data when the subjects 
were on PL-BRJ was 1299.93 (186.05) for when the subjects were on NR-BRJ results was 
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1258.76 (174.01). The estimated treatment effect was -41.17 (-116.74 to 34.40), p=0.27. The 
results show that while at individual time points the HR was higher for when the subjects were 
on PL-BRJ, there was no statistically significant difference in the area under the curve. 
 
Abbreviations: % - percentage, bpm – beats per minute, NR-BRJ – Nitrate-rich Beetroot Juice; 
PL-BRJ – Placebo Beetroot Juice.  
 
Figure 4. Effect of dietary nitrate supplementation on endothelial function  
Percentage change in FMD from baseline and 180 minutes after supplementation with NR-BRJ 
or PL-BRJ. Data presented ate 25th and 75th percentile boxes with the solid line representing 
the median value, and the whiskers the minimum and maximum values. Wilcoxon sign-rank 
test was used to compare the percentage change in FMD in the NR-BRJ (red) and PL-BRJ 
(black) dosing conditions. There was a statistically significant difference in the FMD 
percentage change with an increase in the NR-BRJ group 4.1 (-1.1, 14.8) vs a reduction in the 
PL-BRJ group -5.0 (-10.6, -0.6) %; p = 0.0003. 
 
Abbreviations: FMD – Flow mediated dilatation; NR-BRJ – Nitrate-rich Beetroot Juice; PL-
BRJ – Placebo Beetroot Juice 
 
Figure 5.  Effect of dietary nitrate supplementation on blood pressure parameters 
Change in blood pressure parameters (sBP, dBP and MAP) relative to baseline blood pressure 
three hours prior to dosing with either NR-BRJ or PL-BRJ. Data presented as 25th to 75th 
percentile with the solid line representing the median value, and the whiskers the minimum to 
maximum values. Wilcoxon signed rank test was used to compare blood pressure parameters. 
The median (IQR) change in sBP: NR-BRJ -1.5 (15.0, 10.8) mmHg vs PL-BRJ -0.5 (-10.5, 6.8) 
mmHg; p = 1.0. The median (IQR) in dBP: NR-BRJ 4.0 (-14.0, 7.0) mmHg vs PL-BRJ -1.0 (-
9.3, 5.0) mmHg; p = 0.481. The median (IQR) change in MAP: NR-BRJ -5.0 (-15.3, 6) mmHg 




Abbreviations: BP – Blood Pressure; sBP – systolic blood pressure; dBP – diastolic blood 
pressure; MAP – mean arterial pressure; PL-BRJ – placebo beetroot juice; NR-BRJ – nitrate-
rich beetroot juice 
 
Figure 6. Plasma nitrite and nitrate levels 
Data presented are median (IQR) with whiskers representing minimum to maximum values. 
Plasma NO2
- and NO3
- concentrations were measured at baseline (zero minutes) and 
180minutes after dosing with the interventions. Wilcoxon sign-rank test was used to compare 
change in plasma NO2
- and NO3
- concentrations between intervention groups. Mann-Whitney 
U test was used to compare change in plasma NO2
- and NO3
- concentrations between treatment 
conditions. 
 
Panel A. Changes in plasma NO2- concentrations 
There was a statistically significant difference between baseline plasma NO2
- concentration 
and post dosing with NR-BRJ for plasma NO2
-: pre-dosing plasma NO2
- concentration 0.306 
(0.227, 0.402) µM  vs post-dosing 0.620 (0.488, 0.673) µM; **** p = 0.000076). There was 
also a statistically significant difference between post dosing plasma NO2
- concentration 
between NR-BRJ and PL-BRJ dosing conditions: post dose of NR-BRJ NO2
- concentration 
0.620 (0.488, 0.673) µM vs post dose of PL-BRJ NO2
- concentration 0.306 (0.227, 0.402) µM; 
†††† p = 0.000009. 
 
Panel B. Changes in plasma NO3- levels 
There was a statistically significant difference between baseline plasma NO3
- concentration 
and post dosing with NR-BRJ for plasma NO3
-: pre-dosing plasma NO3
- concentration 62.59 
(41.68, 77.29) μM vs post-dosing 617 (556.25, 725.88) μM; **** p = 0.00004. There was also 
a statistically significant difference between post dosing plasma NO3
- concentration between 
NR-BRJ and PL-BRJ dosing conditions: post dose NR-BRJ NO3
- plasma concentration 617.71 
(556.25, 725.88) μM vs PL-BRJ plasma NO3
- concentration 45.31 (31.39, 58.84) μM; †††† p 




Abbreviations: NR-BRJ – nitrate-rich beetroot juice, PL-BRJ – placebo beetroot juice, µM - 
micromole 
 
Figure 7. Exhaled Nitric Oxide 
Data presented are median (dot) with whiskers representing interquartile range. Red dot and 
line representing NR-BRJ and black dot and line representing PL-BRJ. FENO was measured at 
baseline (study visit 1) and subsequently at intervention visits at seven time points (0minutes, 
30minutes, 60minutes, 90minutes, 120minutes 150minutes and 180 minutes) dosing with 
either NR-BRJ or PL-BRJ. Kruskal-Wallis H Test was used to assess the effect of either NR-
BRJ or PL-BRJ on FENO.  
 
In both intervention groups there was no statistical difference between FENO at baseline 
(measured at study visit 1) and time point zero minutes (measured at intervention visits prior 
to supplementation with intervention beverage). There was a statistically significant difference 
between measured FENO at all subsequent time points post intervention consumption. 
30minutes p = 0.0011, 60minutes p=0.0001, 90minutes p=0.0006, 120minutes p=0.0002, 
150minutes p=0.0002, 180miniutes p=0.0024 (** p ≤ 0.01, *** p ≤ 0.001) (See Supplementary 
Appendix 7). 
 
Abbreviations: FENO – Fractional Exhaled Nitric Oxide; ppb – Parts Per Billion; NR-BRJ – 
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Figure E1. Study flow diagram 
  
Abbreviations: NO3- - Nitrate; BP – Blood 
Pressure; FMD – Flow Mediated Dilatation; 
NO2- - Nitrite; FENO – Fractional Exhaled Nitric 
Oxide; ESWT – Endurance Shuttle Walk Test; 
BRJ – Beetroot Juice; PL - Placebo; GOLD – 
Global Initiative for Chronic Obstructive Lung 
Disease; COPD – Chronic Obstructive 
Pulmonary Disease; eGFR – Estimated 
Glomerular Filtration Rate; sBP – Systolic Blood 
Pressure; ISWT – Incremental Shuttle Walk Test; 




Plasma nitrate/nitrite levels - additional methods 
Plasma NO3
- and NO2
- levels were used as a combined biomarker of NO3
- ingestion, 
metabolism and nitric oxide availability [1, 2]. Plasma samples were obtained on arrival and 
three hours after consumption of either NR-BRJ or PL-BRJ. Samples were obtained by 
venesection of 6 mL of venous blood into lithium heparin tubes. Within five minutes of 
collection the vials were split into 3 mL aliquots, with one mixed with 300 µL of 100 mM stock 
of N-ethylmaleimide (NEM) solution (final concentration 10 mM). The samples were then 
centrifuged at 1,000 g for eight minutes at room temperature. Subsequently, 1 mL of the 
supernatant was aliquoted into 2 mL polypropylene cryotubes, snap frozen with liquid nitrogen 
and stored at -80oC. Plasma nitrate and nitrite concentrations were measured following protein 
precipitation with methanol (1:1 v/v) by a dedicated high-performance liquid chromatography 
(HPLC) system equipped with an anion-exchange column, an in-line Cd/Cu reduction column 
and a post-column diazo coupling reactor coil (Griess reaction) (Eicom NOx analyser, ENO-
20, San Diego, USA) [3].  
 
Oxidative stress – additional methods 
Ferric-reducing ability of plasma (FRAP) 
The FRAP assay is a measure of the antioxidant potential in the extracellular compartment [4]. 
The same plasma samples used for nitrate/nitrate measurement were also used to process this 
assay. Briefly, 150 µl of FRAP reagent (containing 300 mM acetate buffer at pH 3.6, 10 mM 
TPTZ [2,4,6-Tris(2-pyridyl)s-triazine],  20 mM FeCl3 at a ratio of 10:1:1 (v:v:v)) was added to 
5 µl of diluted plasma (1:3, v:v) into a 96-well plate containing 15 µl of MQ water in each well.  
The plate was incubated at  37oC for 30 minutes.  The absorbance at 593 nm was taken 
immediately after incubation using a microplate reader (Spectramax M5, Molecular Devices, 
California USA).  FRAP values for the samples were obtained by comparing the absorbance at 
593 nm with the known concentrations in the standards (FeSO4·7H2O).  
 
Thiobarbituric acid-reactive substance (TBARS) 
TBARS is a measure of lipid oxidation and is measured using a TBARS assays [5]. The same 
plasma samples used for nitrate/nitrate measurement were also used to process this assay. In 
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brief the TBARS assay incorporated the use of an malodialdehyde (MDA) source such as 
1,1,3,3 Tetramethoxypropane after hydrolysis as standard, 0.6N tricholoroacetic acid as the 
acid reagent and thiobarbituric acid (0.26g in 50 mL glacial acetic acid) as colour reagent. Prior 
to analysis, samples were deproteinised by acid precipitation by taking 300 uL samples and 
adding an equal volume of acid reagent, mixed and incubated for 15 min at room temperature.  
The supernatant was isolated by 4 min centrifugation at > 12,000 x g.  The resulting supernatant 
was further treated with colour reagent (2:1, v:v), incubated for 1h at 100°C and immediately 
cooled on ice for 10 min.  Treated samples were plated into 96-well microplates and absorbance 
readings were read at 532 nm using a microplate reader (Spectramax M5, Molecular Devices, 
California USA).  TBARS values for the samples were obtained by comparing the absorbance 
with known concentrations of MDA standards.   
 
Total free thiols per protein 
Systemic oxidative stress can be measured as the depletion of the free thiol pool in plasma [6]. 
The same plasma samples used for nitrate/nitrate measurement were also used to process this 
assay. Thiol groups were measured as previously described [7, 8]. In brief, 75 µl plasma 
samples were diluted 1:4 (v:v) with a 0.1 M Tris buffer (pH 8.2) and transferred 90 uL of 
diluted sample to a 96-well microplate. Using a microplate reader (Molecular Devices 
Spectramax M5, California, USA), background absorption was measured at 412 nm with a 
reading at 630 nm for baseline correction. Subsequently, 20 µl 1.9 mM 5,5-Dithio-bis(2-
nitrobenzoic acid) [DTNB] in 0.1 M phosphate buffer (pH 7) was added to the samples and 
standards. Following 20 minutes of incubation at room temperature while mixing, absorption 
was remeasured  at 412 and 630 nm. The concentration of total free thiols in the samples was 
determined by comparing their absorbance reading to that of an L-cysteine standard before and 
after addition of DTNB to samples/satandards. 
 
Endothelial function - additional methods 
Endothelial function was assessed using flow medicated dilatation (FMD) of the brachial artery 
[9] using a high-resolution doppler ultrasound (GE Logiq 3, GE Medical Systems, Milwaukee, 
Wisconsin, USA) and a 10 MHz multi-frequency linear array probe were used in B-mode. 
Brachial artery diameter was measured at baseline and sequentially after release of circulatory 
arrest of the upper arm over a period of 120 seconds [10], three hours after NR-BRJ/PL-BRJ 
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consumption. All measurements were performed by a single trained operator. Circulatory arrest 
was generated via a rapid cuff inflation system (Hokanson, Bellevue, WA, USA), which was 
positioned proximal to the brachial artery and rapidly inflated to 250 mmHg for five minutes. 





Table E1. Exercise oxygen saturations and heart rate analysis  
Measure PL-BRJ (n=18) NR-BRJ (n=18) 
Saturations (%) 
 Rest 96 (90, 97) 96 (92, 97) 
 Warm-up 91 (89, 95) 94 (90, 95) 
 Isotime 92 (89, 94) 96 (93, 97) 
 Peak 88 (86, 92) 94 (91, 96) 
 Recovery 97 (92, 98) 98 (96, 98) 
Heart Rate (bpm) 
 Rest 86 (74, 88) 88 (78, 91) 
 Warm-up 103 (88, 108) 96 (88, 102) 
 Isotime 111 (103, 123) 109 (96, 116) 
 Peak 104 (96, 111) 101 (112) 
 Recovery 91 (79, 101) 89 (81, 98) 
 
The area under the curve for each treatment group was estimated and reported as mean (SD). 
The results for Saturations for when the subjects were on placebo beetroot juice were 1161.85 
(47.59) and the results for when the subjects on Nitrate-rich beetroot juice were 1205.54 (46.39). 
The treatment effect was estimated to be 43.69 (29.09 to 58.28) p < 0.0001. The results suggest 
that on the average the area under the curve for saturations was higher when on Nitrate-rich 
beetroot juice than when on placebo. These differences tended to show more during the Isotime 
and peak periods. 
 
The mean (SD) area under the curve for the HR data when the subjects were on placebo 
beetroot juice was 1299.93 (186.05) for when the subjects were on Nitrate-rich beetroot juice 
results was 1258.76 (174.01). The estimated treatment effect was -41.17 (-116.74 to 34.40), 
p=0.27. The results show that while at individual time points the HR was higher for when the 
subjects were on Placebo, there was no statistically significant difference in the area under the 
curve. 
 





Table E2. Between intervention analysis of plasma nitrite and nitrate 




0.32 (0.25, 0.37)  
 
0.34 (0.22, 0.39)  
Baseline Nitrate 
(µM) 
51.89 (38.98, 62.28)  62.59 (41.68, 77.29)  
180 Minute Nitrite 
(µM) 
0.31 (0.23, 0.47)  0.60 (0.48, 0.67)  
180 Minute Nitrate 
(µM) 
45.31 (31.39, 58.84)  617.71 (508.6, 725.88)  
Difference in 
Nitrite (µM) 
from baseline to 
180 minutes 
0.023 (-0.044, 0.079) 0.276 (0.144, 0.463)               
Difference in 
Nitrate (µM) 
from baseline to 
180 minutes 
-4.61 (-9.63, 6.23) 543.25 (441.78, 674.23) 
 
Results are reported as median (IQR). 
The treatment effect of Nitrate was estimated with the Hodges-Lehman estimate and it was 550 
(461 to 639) µM. The results suggest that the was a higher for when the subjects were on 
Nitrate-rich beetroot juice than when they were on placebo and this change was statistically 
significant, p=0.0003. 
 
The treatment effect of Nitrite was estimated with the Hodges-Lehman estimate and it was 
0.248 (0.138 to 0.408) µM. The results suggest that the was a higher for when the subjects were 
on Nitrate-rich beetroot juice than when they were on placebo and this change was statistically 
significant, p=0.0011. 
 










SD SEM %CV 
Mean 
(µM) 
SD SEM %CV 
NEM Stock Solution 0.07 0.03 0.02 45.41 22.37 2.33 1.34 10.40 
Cryotube 0.09 0.02 0.01 17.15 2.44 0.53 0.31 22.33 
PL-BRJ 195.86 2.12 1.22 1.08 55.05 0.68 0.39 1.24 




- in NEM Stock Solution, Cryotubes, Cryotubes with 0.9% 
Sodium Chloride, PL-BRJ and NR-BRJ.  
 
Abbreviations: NEM – N-Ethylmaleimide; SD – Standard Deviation; SEM – Standard Error 
Mean; %CV – Percentage Coefficient of Variation; PL-BRJ – Placebo Beetroot Juice; NR-




Table E4. Fractional Exhaled Nitric Oxide (FeNO) 
 FENO post NR-
BRJ (ppb) 
FeNo post PL-BRJ  
(ppb) 
Baseline 18.5 (15.0, 21.5) 18.0 (14.0, 22.5) 
0 Minutes 19.5 (16.0, 22.5) 19.0 (15.0, 22.5) 
30 Minutes 44.5 (27.0, 63.0) 21.0 (17.0, 25.5) 
60 Minutes 49.5 (33.5, 78.5) 21.5 (17.0, 29.0) 
90 Minutes 54.0 (26.5, 90.0) 19.0 (15.0, 27.5) 
120 Minutes 49.0 (32.5, 56.0) 20.5 (16.0, 24.5) 
150 Minutes 59.0 (33.5, 84.0) 20.0 (17.0, 32.5) 
100 Minutes 55.0 (35.0, 76.5) 21.5 (15.5, 27.5) 
 
FENO levels measured at baseline (visit 1) and subsequently at intervention visits (visits 3 and 
4) at time point zero minutes prior to dosing with either PL-BRJ or NR-BRJ and subsequently 
every 30 minutes until 180 minutes post dosing. Data presented: median (IQR). 
 
The AUC was calculated for each treatment group and compared to estimate the treatment 
effect using the Hodges-Lehman estimate. The median (IQR) AUC for when the subjects were 
on placebo was 3622.5 (3181.9, 4796.9) and the corresponding results for when the subjects 
were on Nitrate-rich beetroot juice was 9440.6 (6273.8, 11831.3) and the treatment effect with 
its 95% CI was 5407 (3096 to 7576), p=0.0011. The results suggest that the FeNO levels while 
the subjects were on Nitrate-rich beetroot juice were significantly higher than when they were 
on placebo  
Abbreviations: FENO – Fractional Exhaled nitric Oxide; IQR – Interquartile Range; AUC – 




Figure E2. Primary Outcome Order Effect 
 































Change in ESWT time (seconds) when testing for intervention order effect, if PL-BRJ was 
applied first or NR-BRJ. Data presented median (line) and interquartile range (whiskers) with 
as individual data points (dots). Mann-Whitney U test, the median (IQR) change in ESWT time 
if PL-BRJ was applied first was 60.0 (21.8, 88.4) seconds, compared to 43.1 (14.03, 155.3) 
seconds, if NR-BRJ was applied first; p = 0.82. 
Abbreviations: ESWT – Endurance Shuttle Walk Test; PL-BRJ – Placebo Beetroot Juice; NR-




Results E1. Effect of dietary nitrate supplementation on endurance shuttle walk time  
There is a clear outlier in this dataset. When this individual’s data was removed from analysis, 
all individuals still walked further following consumption the NO3
--rich BRJ. There was a 
statistically significant difference between the median (IQR) ESWT time with the outlier 
removed; NO3
--rich BRJ 193.8 (145.5, 389.6) seconds vs PL 158.2 (121.6, 236.6) seconds; p 
= 0.0001. Regarding this specific individual at baseline assessment their best ISWT distance 
was 370 meters, using the ESWT conversion table the ESWT speed was calculated as 4.65 
km/h which equates to ESWT level 11. All individuals undertook a practice ESWT, this 
individual’s practice ESWT time was 599 seconds. The ESWT time that this individual 
achieved following consumption of the placebo beverage was 785 seconds. For both ESWT 
this individual reported peak Borg Dyspnoea scale of 8.  This individual’s data was included 












































































































































































Measures of oxidative stress for PL-BRJ and NR-BRJ Dosing conditions. Data presented as 
Data presented are median and interquartile range (box) with whiskers representing minimum 
to maximum values.  Plasma samples were measured at baseline (zero minutes) and 180 
minutes after dosing. Wilcoxon sign-rank test was used to compare change in measures of 
oxidative stress between intervention groups. Mann-Whitney U test was used to compare 
change in measures of oxidative stress between treatment conditions. 
 
Panel A. Ferric reducing ability of plasma (FRAP) 
There was no statistically significant difference between interventions for baseline and post 
intervention FRAP. Baseline FRAP PL-BRJ: 1028 (762.9, 1195) µM vs FRAP NR-BRJ: 927.7 
(790.2, 1064) µM; p = 0.7. Post intervention FRAP PL-BRJ: 930.2 (836.8, 1073) µM vs FRAP 
NR-BRJ: 1018 (853.0, 1125) µM; p = 1.0. (Wilcoxon sign-rank test) 
 
There was no statistically significant difference between baseline FRAP levels and post dosing 
levels with either PL-BRJ and NR-BRJ. FRAP PL-BRJ: 1028 (762.9, 1195) µM vs post dosing 
930.2 (836.8, 1073) µM; p = 0.9. FRAP NR-BRJ: 927.7 (790.2, 1064) µM vs post dosing 1018 
(853.0, 1125) µM; p = 0.3. (Mann-Whitney U test). 
 
Panel B. Thiobarbituric acid-reactive substance (TBARS) 
There was no statistically significant difference between interventions for baseline and post 
intervention TBARS. Baseline TBARS PL-BRJ: 1.443 (1.102, 2.940) mM vs TBARS NR-BRJ: 
1.450 (1.007, 2.613) mM; p = 0.8. Post intervention TBARS PL-BRJ: 0.971 (0.766, 1.614) 
mM vs TBARS NR-BRJ: 1.499 (0.855, 3.209) mM; p = 0.4. (Wilcoxon sign-rank test) 
 
There was no statistically significant difference between baseline TBARS levels and post 
dosing levels with either PL-BRJ and NR-BRJ. TBARS PL-BRJ: 1.443 (1.102, 2.940) mM vs 
post dosing 0.971 (0.766, 1.614) mM; p = 0.8. TBARS NR-BRJ: 1.450 (1.007, 2.613) mM vs 




Panel C. Total free thiols (TFT) per protein  
There was no statistically significant difference between interventions for baseline and post 
intervention TFT per protein. Baseline TFT per protein PL-BRJ: 6.754 (6.328, 8.342) µmol.g-
1 protein vs TFT per protein NR-BRJ: 7.284 (6.508, 7.960) µmol.g-1 protein; p = 0.9. Post 
intervention TFT per protein PL-BRJ: 6.942 (5.768, 8.026) µmol.g-1 protein vs TFT per protein 
NR-BRJ: 7.079 (5.961, 8.115) µmol.g-1 protein; p = 0.5. (Wilcoxon sign-rank test) 
 
There was no statistically significant difference between baseline TFT per protein levels and 
post dosing levels with either PL-BRJ and NR-BRJ. TFT per protein PL-BRJ: 6.754 (6.328, 
8.342) µmol.g-1 protein vs post dosing 6.942 (5.768, 8.026) µmol.g-1 protein; p = 0.1. TFT per 
protein NR-BRJ: 7.284 (6.508, 7.960) µmol.g-1 vs post dosing 7.079 (5.961, 8.115) µmol.g-1 
protein; p = 0.4. (Mann-Whitney U test). 
 
Abbreviations: FRAP - Ferric Reducing Ability of Plasma; TBARS - Thiobarbituric Acid-
Reactive Substance; TFT – Total Free Thiols; PL-BRJ – Placebo Beetroot Juice; NR-BRJ – 
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